275 Armand-Frappier Boulevard
Laval, QC H7V 4A7
Full-time employees: 40
|Mr. Roberto Francesco Bellini||Pres, CEO & Director||353.03k||N/A||1980|
|Mr. Ramzi Benamar||Chief Financial Officer||607.33k||N/A||1973|
|Dr. Denis Garceau||Chief Scientific Officer||431.87k||N/A||1957|
|Mr. Tony Matzouranis||Sr. VP of Bus. Devel.||272.89k||N/A||1973|
|Dr. Catherine M. Bonuccelli M.D.||Chief Medical Officer||703.77k||N/A||1958|
|Dr. Andreas Orfanos FFPM, M.B.B.Ch, MBA||Chief Operating Officer||N/A||N/A||1959|
|Mr. Daniel Matthews||Director of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Francois Desjardins C.A., CPA, CPA, CA||Sr. VP of Fin.||N/A||N/A||1963|
|Mr. Sebastien Roy||Corp. Sec.||N/A||N/A||1976|
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
BELLUS Health Inc.’s ISS governance QualityScore as of 1 July 2022 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder rights: 7; Compensation: 8.